SCHEMBL2295771

SCHEMBL2295771

N#Cc1cccc(N2C(=O)CN3C(=O)CCC32)c1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
NSD2 O96028 1/20 0.42
NOTUM Q6P988 2/20 0.41
DRD2 P14416 4/20 0.40
DRD3 P35462 4/20 0.40
FADS1 O60427 3/20 0.40
METAP1 P53582 1/20 0.40
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
KCNH2 Q12809 2/20 0.37
DRD4 P21917 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998001 0.83 HTR7 (0.41) CTSGCMA1KCNH2
SCHEMBL3005601 0.81 ALDH1A1 (0.41) ALOX5
SCHEMBL3001653 0.80 NPC1 (0.41)
SCHEMBL3006660 0.80 POLB (0.41) ALOX5FADS1METAP1
SCHEMBL3002692 0.80 L3MBTL1 (0.50) ALOX5NOTUM
SCHEMBL2996862 0.78 MGLL (0.38) ALOX5NOTUM
SCHEMBL3003653 0.77 KMT2A (0.46) ALOX5CTSGCMA1
SCHEMBL16480396 0.77 FADS1 (0.48) ALOX5NSD2NOTUMDRD2DRD3
SCHEMBL3001196 0.76 HTR7 (0.47) ALOX5NOTUM
SCHEMBL3002934 0.76 NOTUM (0.41) NOTUMDRD2DRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US claimed
EP-1608655-B8 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS BRANE DISCOVERY SRL IN LIQUIDA (IT) 2008-10-15 EP claimed
EP-1608655-B1 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH SRL (IT) 2008-07-16 EP claimed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US claimed
EP-1608655-A2 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH S.R.L. (IT) 2005-12-28 EP claimed
WO-2004085438-A2 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH S.R.L. (IT) 2004-10-07 WO claimed
EP-2857017-B1 Use of dimiracetam in the treatment of chronic pain NEUROTUNE AG (CH) 2016-05-25 EP disclosed
EP-2857017-A2 Use of dimiracetam in the treatment of chronic pain Neurotune AG (CH) 2015-04-08 EP disclosed
EP-2146706-B1 USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN NEUROTUNE AG (CH) 2015-02-25 EP disclosed
EP-2620149-A2 Use of dimiracetam in the treatment of chronic pain Neurotune AG (CH) 2013-07-31 EP disclosed
US-8222241-B2 Use of dimiracetam in the treatment of chronic pain NEUROTUNE AG (CH) 2012-07-17 US disclosed
US-20110251250-A1 USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN FARINA CARLO 2011-10-13 US disclosed
US-7989421-B2 Use of dimiracetam in the treatment of chronic pain NEUROTUNE AG (CH) 2011-08-02 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof FARINA CARLO 2009-06-25 US disclosed
US-7544705-B2 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2009-06-09 US disclosed
WO-2008125674-A1 USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN NEUROTUNE AG (CH) 2008-10-23 WO disclosed
EP-1608655-B1 PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS NIKEM RESEARCH SRL (IT) 2008-07-16 EP disclosed
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents NEUROTUNE AG (CH) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251250-A1 USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN DIMT1, OPRK1, OPRM1 ALOX5 1515/4885NSD2 1565/4885NOTUM 820/4885
US-20090163565-A1 Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof OPRL1, GRIN3B, GRIN3A ALOX5 571/4885NSD2 3112/4885NOTUM 696/4885
US-20070027137-A1 Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents GRIN3A, GRIN1, GRIN3B ALOX5 467/4885NSD2 2438/4885NOTUM 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.